Research and Markets: Virus-Like Particles (VLPs) Trends 2014 Report

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/4ch4b3/viruslike) has announced the addition of the "Virus-Like Particles (VLPs) Trends" report to their offering.

The report analyzes and presents an overview of Virus-Like Particles (VLPs) market worldwide. "Virus-like particles or VLPs bear high structural resemblance to viruses, though completely non-infectious in nature due to the absence of viral genetic material. While lacking the DNA material, VLPs retain key immunological characteristics of viruses including particulate structures; repetitive surfaces; and capability to induce innate immunity by activating molecular-pattern pathogen-associated recognition receptors."

The report also provides a review of types, medium of production, quantification, applications, and advantages of VLPs over conventional vaccines along with strategic industry activities of major companies worldwide.

In addition, 10 companies operating in the Direct Attached Storage (DAS) arena worldwide are profiled, including

  • Cytos Biotechnology
  • Medicago
  • Novavax
  • Redbiotec
  • Virometix
  • VLPbio
  • The Vaccines Company

Key Topics Covered

1. VIRUS-LIKE PARTICLES - A TECHNOLOGY OVERVIEW

  • Virus-like Particles: An Introduction
  • Ability to Elicit Immune Response: A Unique Characteristic of VLPs
  • Virus-like Particles: Types
  • Mycovirus VLPs
  • Chimeric VLPs
  • Empty Virus-like Particles (eVLPs)
  • Functional Influenza VLPs
  • Respiratory Syncytial VLPs
  • Rabies Glycoprotein VLPs
  • Virus-like Particles: Medium of Production
  • Insect Cell Lines
  • Plant Cell Lines
  • Yeast Cells
  • Heterologous Expression Systems
  • Virus-like Particles: Quantification
  • Virus-like Particles: Applications
  • Vaccine Development
  • Treatment of Chronic Diseases
  • Advantages of VLP-based Vaccines over Conventional Vaccines
  • Comparison with Recombinant Protein Vaccines
  • Comparison with Chicken Egg-based Vaccines
  • Advantage of Using VLPs in Development of Flu Vaccine
  • Use of VLPs in Nanotechnology for Targeted Drug Delivery

2. NOTEWORTHY INDUSTRY ACTIVITY

  • Medicago and a Leading Pharmaceutical Company Ink Loan Agreement
  • Medicago Develops New VLP-based Vaccine Candidate againstH7N Virus
  • Novavax Commences Animal Studies on H7N9 VLP Vaccine
  • Medicago to Increase Production Capacity of Pilot Facility
  • Medicago Completes Preclinical Studies on New VLP Vaccine Candidate against Rabies
  • Novavax Concludes Phase I Clinical Trials on A/H5N1 Vaccine Candidate
  • Medicago and USAMRIID Ink Research Collaboration Agreement
  • Novavax Secures Contract from Biomedical Advanced Research and Development Authority
  • Medicago and PT Bio Farma Ink Memorandum of Understanding
  • Medicago Files Patent Applications for New VLP/Recombinant Proteins Production Methods
  • Novavax Receives US Patent for Influenza VLP Vaccine Technology
  • Novavax Concludes Phase II Clinical Trial on Trivalent
  • Seasonal Influenza VLP-based Vaccine Candidate

3. MARKET PARTICIPANTS

4. APPENDIX

For more information visit http://www.researchandmarkets.com/research/4ch4b3/viruslike

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals